Hierarchy-of-models Approach for Aggregated-Force Attrition

Proceedings of the 2000 Winter Simulation Conference J. A. Joines, R. R. Barton, K. Kang, and P. A. Fishwick, eds.This paper presents some innovations for overcoming shortcomings in the current state-of-the-art for the hierarchy-of-models approach to modeling aggregatedforce attrition in ground-combat models. The basic concept of such an approach for modeling large-scale system behavior is presented, together with the theoretical underpinnings for modeling attrition in large-scale ground combat. The output of an entity-level discrete-event combat simulation is fit to a Lanchester-type aggregatedreplay model. Use of a reliable statistical-estimation technique for determining model parameters is emphasized. The main innovation is to show how use of more detailed output data (e.g. line-of-sight (LOS) data) from the high-resolution simulation allows one to develop maximum-likelihood estimates. The methodology is applied to a current high-resolution DoD combat model, and a Lanchester-type aggregated-force replay model is developed

Extending the state-of-the-art for the COMAN/ATCAL methodology

This thesis reviews currently existing attrition methodologies and critically examines the (ATtrition CALibration) ATCAL approach for heterogeneous force mixes. Lanchester attrition-rate coefficients must be calibrated for use in ATCAL. When the aggregated combat results from a Lanchester-type attrition model agree with the results of a high-resolution simulation, for a particular mix of weapons on either side, the equation is said to be calibrated. Combat scenario runs are made in the high-resolution JANUS combat model. A maximum likelihood estimation approach (COMAN), which incorporates target priority and availability information, is used to estimate the Lanchester attrition rates in the ATCAL model. A continuous-time, three-state Markov chain model of target acquisition in JANUS is used to obtain the target availability parameters required in the COMAN approach. Bootstrap confidence intervals are developed for the attrition-rate estimates and the target availability parameters. The ability of the ATCAL methodology to replay JANUS results in an aggregated, heterogeneous-force replay model is investigated. These developments have the potential for allowing high-resolution simulation results to be extrapolated to a wider spectrum of conditions (e.g., force mixes) than currently possible by virtue of the more detailed nature of the aggregated-replay model involved.http://www.archive.org/details/extendingstateof00yildFirst Lieutenant, Turkish ArmyApproved for public release; distribution is unlimited

A SURVEY OF PATIENT PREPARATION AND TECHNIQUE OF ULTRASOUND-GUIDED PROSTATE BIOPSY: A MULTICENTER STUDY OF UROONCOLOGICAL ASSOCIATION

Introduction: Ultrasound-guided prostate biopsy is the standard method for the diagnosis of prostate cancer. The aim of the present survey is to assess the variability in patient preparation and technique of ultrasound-guided prostate biopsy among Turkish Urologists

Turkish National Severe Congenital Neutropenia Registry

58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) -- DEC 03-06, 2016 -- San Diego, CAWOS: 000394452701110Amer Soc HematolTUBITAKTurkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK)Yilmaz Karapinar: TUBITAK: Research Funding

A Retrospective Analysis of 83 Patients with Testicular Mass Who Underwent Testis-Sparing Surgery: The Eurasian Uro-oncology Association Multicenter Study

Introduction: Herein, we analyzed the histopathological, oncological and functional outcomes of testis-sparing surgery (TSS) in patients with distinct risk for testicular cancer. Methods: This is a multicenter retrospective study on consecutive patients who underwent TSS. Patients were categorized in high- or low-risk testicular germ cell tumor (TGCT) according to the presence/absence of features compatible with testicular dysgenesis syndrome. Histology was categorized per size and risk groups. Results: TSS was performed in 83 patients (86 tumors) of them, 27 in the high-risk group. Fifty-nine patients had a non-tumoral contralateral testis present. Sixty masses and 26 masses were benign and TGCTs, respectively. No statistical differences were observed in mean age (30.9 ± 10.32 years), pathological tumor size (14.67 ± 6.7 mm) between risk groups or between benign and malignant tumors (p = 0.608). When categorized per risk groups, 22 (73.3%) and 4 (7.1%) of the TSS specimens were malignant in the high- and low-risk patient groups, respectively. Univariate analysis showed that the only independent variable significantly related to malignant outcome was previous history of TGCT. During a mean follow-up of 25.5 ± 22.7 months, no patient developed systemic disease. Local recurrence was detected in 5 patients and received radical orchiectomy. Postoperative testosterone levels remained normal in 88% of those patients with normal preoperative level. No erectile dysfunction was reported in patients with benign lesions. Conclusion: TSS is a safe and feasible approach with adequate cancer control, and preservation of sexual function is possible in 2/3 of patients harboring malignancy. Incidence of TGCT varies extremely between patients at high and low risk for TGCT requiring a careful consideration and counseling

Homozygous c.130-131 ins A (pW44X) mutation in the HAX1 gene as the most common cause of congenital neutropenia in Turkey: Report from the Turkish Severe Congenital Neutropenia Registry

WOS: 000478208700001PubMed ID: 31321910Background Severe congenital neutropenia is a rare disease, and autosomal dominantly inherited ELANE mutation is the most frequently observed genetic defect in the registries from North America and Western Europe. However, in eastern countries where consanguineous marriages are common, autosomal recessive forms might be more frequent. Method Two hundred and sixteen patients with severe congenital neutropenia from 28 different pediatric centers in Turkey were registered. Results The most frequently observed mutation was HAX1 mutation (n = 78, 36.1%). A heterozygous ELANE mutation was detected in 29 patients (13.4%) in our cohort. Biallelic mutations of G6PC3 (n = 9, 4.3%), CSF3R (n = 6, 2.9%), and JAGN1 (n = 2, 1%) were also observed. Granulocyte colony-stimulating factor treatment was given to 174 patients (80.6%). Two patients died with infectious complications, and five patients developed myelodysplastic syndrome/acute myeloblastic leukemia. The mean (+/- mean standard error) follow-up period was 129.7 +/- 76.3 months, and overall survival was 96.8% (CI, 94.4-99.1%) at the age of 15 years. In Turkey, severe congenital neutropenia mostly resulted from the p W44X mutation in the HAX1 gene. Conclusion In Turkey, mutation analysis should be started with HAX1, and if this is negative, ELANE and G6PC3 should be checked. Because of the very high percentage of consanguineous marriage, rare mutations should be tested in patients with a negative mutation screen.Scientific and Technological Research Council of Turkey (TUBITAK)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); Turkish Pediatric Hematology AssociationThis study was supported by Scientific and Technological Research Council of Turkey (TUBITAK) and the Turkish Pediatric Hematology Association

COVID-19 associated multisystemic inflammatory syndrome in 614 children with and without overlap with Kawasaki disease-Turk MIS-C study group.

Multisystemic inflammatory syndrome (MIS-C) diagnosis remains difficult because the clinical features overlap with Kawasaki disease (KD). The study aims to highlight the clinical and laboratory features and outcomes of patients with MISC whose clinical manifestations overlap with or without KD. This study is a retrospective analysis of a case series designed for patients aged 1 month to 18 years in 28 hospitals between November 1, 2020, and June 9, 2021. Patient demographics, complaints, laboratory results, echocardiographic results, system involvement, and outcomes were recorded. A total of 614 patients were enrolled; the median age was 7.4 years (interquartile range (IQR) 3.9-12 years). A total of 277 (45.1%) patients with MIS-C had manifestations that overlapped with KD, including 92 (33.3%) patients with complete KD and 185 (66.7%) with incomplete KD. Lymphocyte and platelet counts were significantly lower in patients with MISC, overlapped with KD (lymphocyte count 1080 vs. 1280 cells x mu L, p = 0.028; platelet count 166 vs. 216 cells x 10(3)/mu L, p 12 years reduced the risk of overlap with KD by 66% (p < 0.001, 95% CI 0.217-0.550), lethargy increased the risk of overlap with KD by 2.6-fold (p = 0.011, 95% CI 1.244-5.439), and each unit more albumin (g/dl) reduced the risk of overlap with KD by 60% (p < 0.001, 95% CI 0.298-0.559)